



# Ambrosia Biosciences

April 2026

*Ambrosia is developing orally available small-molecule therapies targeting GLP-1 and related receptors for safe, effective, affordable metabolic treatment, enabling combination and personalized patient care.*

# Why Oral Small Molecules?



## Peptides - Inherent Delivery and Scaling Challenges:


- **Poor oral bioavailability** typically necessitates injection - limiting patient adoption and adherence
- Oral versions require large doses and offer **inconsistent performance** in real world
- **Manufacturing** is complex and resource-intensive
- Delivery devices **increase cost and waste**
- **Cold-chain requirement** hampers distribution, particularly at global scale



## Small Molecules - Patient-Friendly Delivery with Scalable Economics:

- **Oral dosing preferred** by patients and supports flexible, personalized titration
- **Scalable, lower COGs** manufacturing
- **Stable** at room temperature
- **No delivery device**; less waste

# Oral Small Molecule Discovery Pipeline



## GLP1R Agonist

DC/IND-enabling studies

Developing a differentiated GLP-1 molecule demonstrating best-in-class potential, based on a novel structural approach and emphasis on lower effective human dosing, superior 24-hour target coverage, and improved combinability.

## GIPR Antagonist

Discovery


Combination dosing with GLP1-RA to amplify efficacy while maintaining tolerability, as well as potential for maintenance dosing.

## Amylin Agonist

Discovery

Once daily monotherapy or in combination with synergistic therapies, such as GLP-1RA.

# Ambrosia Snapshot

Proven drug discovery team from 

Investors:

BVF Partners, Boulder Ventures, Blue Owl Healthcare Opp, Deep Track, Redmile, Janus, Samsara and Merck

## Team:

- Founding scientific team with a proven track record in all stages of structure-based drug discovery
- Contributed to *30 IND filings on 25 NMEs and 7 FDA approvals*

## Boulder, CO Facilities (24,000 sq. ft.):

- **Fully integrated chemistry & biology operations** enabling rapid iteration
- **NMR, structural biology, & AI-enabled molecular design** supporting GPCR discovery
- **BSL-2 & in vitro ADME labs** for rapid preclinical screening

# Ambrosia Team

Experienced drug developers and company builders



**Nick Traggis**  
Founder and CEO



**Patrice Lee, PhD**  
President, R&D



**Erik Hicken, PhD**  
Head of Chemistry



**Andrea Flynn, PhD**  
Chief Business Officer




**Faraz Naqvi, MD**  
Founder, Medical Director



**Ben Carver**  
Founder, General Counsel



**Kenny Edwards**  
Vice President, Finance



**Matthew Martinson**  
Vice President, Operations



# Ambrosia Team

## Industry leading Board of Directors



**Kyle Lefkoff**  
Founder and Chairman



**William Marshall, PhD**  
Founder and Director



**David Snitman, PhD**  
Founder and Director




**John Orwin**  
Founder and Director



**Sara Clarke, PhD**  
Director



**Jason Haddock**  
Director



**Nick Traggis**  
Founder and CEO



# Ambrosia Team

## Industry leading Scientific Advisory Board



**John Mayer, PhD**  
 Founder and Chairman of Scientific  
 Advisory Board



**Richard DiMarchi, PhD**  
 Scientific Advisory Board



**Thomas Hughes, PhD**  
 Scientific Advisory Board



**Randy Seeley, PhD**  
 Scientific Advisory Board



**Kieran Chacko, PhD**  
 Founder and Strategic Advisor



**Nick Saccomano, PhD**  
 Strategic Advisor



# Ambrosia Timeline



## \$25MM Series A Financing

- Led by Merck, BVF Partners and Boulder Ventures
- Recruit founding science team from Array/Pfizer

## Nominated Development Candidate: GLP-1 RA

- Initiate IND enabling studies

## \$100M Series B Financing

- Led by Blue Owl Healthcare Opportunities, Redmile, Deep Track Capital
- Advance small molecule pipeline into clinic

2024

2025

2026

## Began Laboratory Operations in Boulder, CO

- Begin to interrogate small molecule candidates

## 2026: Continue to Advance Oral Small Molecule Pipeline

- GLP-1RA
- GIPR
- Amylin
- Undisclosed



Contact:  
[info@ambrosia.health](mailto:info@ambrosia.health)